Researchers sought to determine whether postoperative radiotherapy would be safe and effective for patients who receive spinal surgery osteolytic lesions of multiple myeloma.
News
Researchers sought to evaluate the effects of social support on HRQoL among patients with multiple myeloma or its precursor diseases.
Belantamab mafodotin plus bortezomib and dexamethasone could be a new standard of care for second-line or later treatment of relapsed or refractory multiple myeloma, according to researchers.
Researchers sought to confirm the effectiveness of a novel tool designed to assist patients with MM in assessing their preferences regarding treatment.
Triplet therapy of belantamab mafodotin, bortezomib, dexamethasone beneficial for relapsing or refractory multiple myeloma.
Diabetes mellitus may contribute to the higher incidence of multiple myeloma seen in Black patients, research suggests.
An analysis of data from the Black Women’s Health Study sought to determine impact of early adulthood BMI on risk for multiple myeloma in this population.
Low platelet count, ISS III, higher WHO performance status, age older than 60 years are risk factors for severe infection/death.
Researchers sought to determine whether linvoseltamab would improve responses in patients with relapsed/refractory multiple myeloma.
Researchers sought to determine whether bridging therapy in multiple myeloma would improve outcomes with CAR-T therapy.